Charles Schwab Investment Management Inc Ligand Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

  • $429 Billion
  • Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 149,776 shares of LGND stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,776
Previous 161,480 7.25%
Holding current value
$12.6 Million
Previous $11.5 Million 5.06%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
SELL
$68.64 - $89.2 $803,362 - $1.04 Million
-11,704 Reduced 7.25%
149,776 $10.9 Million
Q4 2023

Feb 06, 2024
BUY
$49.57 - $72.63 $212,804 - $311,800
4,293 Added 2.73%
161,480 $11.5 Million
Q3 2023

Nov 08, 2023
BUY
$58.86 - $72.67 $162,512 - $200,641
2,761 Added 1.79%
157,187 $9.42 Million
Q2 2023

Aug 09, 2023
BUY
$69.53 - $79.33 $507,082 - $578,553
7,293 Added 4.96%
154,426 $11.1 Million
Q1 2023

May 11, 2023
SELL
$65.67 - $77.08 $1.41 Million - $1.66 Million
-21,493 Reduced 12.75%
147,133 $10.8 Million
Q4 2022

Feb 13, 2023
BUY
$61.72 - $96.74 $496,784 - $778,660
8,049 Added 5.01%
168,626 $11.3 Million
Q3 2022

Nov 14, 2022
BUY
$0.01 - $107.56 $15 - $162,738
1,513 Added 0.95%
160,577 $13.8 Million
Q2 2022

Aug 15, 2022
BUY
$74.52 - $117.06 $341,525 - $536,485
4,583 Added 2.97%
159,064 $14.2 Million
Q1 2022

May 13, 2022
BUY
$94.99 - $151.56 $120,447 - $192,178
1,268 Added 0.83%
154,481 $17.4 Million
Q4 2021

Feb 11, 2022
BUY
$127.69 - $165.85 $1.21 Million - $1.57 Million
9,455 Added 6.58%
153,213 $23.7 Million
Q3 2021

Nov 16, 2021
BUY
$102.33 - $144.73 $673,843 - $953,047
6,585 Added 4.8%
143,758 $20 Million
Q2 2021

Aug 16, 2021
BUY
$113.03 - $155.64 $864,340 - $1.19 Million
7,647 Added 5.9%
137,173 $18 Million
Q1 2021

May 17, 2021
BUY
$99.52 - $215.83 $838,057 - $1.82 Million
8,421 Added 6.95%
129,526 $19.7 Million
Q4 2020

Feb 16, 2021
BUY
$80.55 - $106.05 $63,876 - $84,097
793 Added 0.66%
121,105 $12 Million
Q3 2020

Nov 13, 2020
BUY
$89.56 - $126.72 $1.54 Million - $2.18 Million
17,216 Added 16.7%
120,312 $11.5 Million
Q2 2020

Aug 14, 2020
SELL
$68.28 - $123.65 $67,255 - $121,795
-985 Reduced 0.95%
103,096 $11.5 Million
Q1 2020

May 15, 2020
SELL
$63.37 - $107.88 $372,298 - $633,795
-5,875 Reduced 5.34%
104,081 $7.57 Million
Q4 2019

Feb 07, 2020
SELL
$96.94 - $113.59 $2.96 Million - $3.46 Million
-30,486 Reduced 21.71%
109,956 $11.5 Million
Q3 2019

Nov 08, 2019
SELL
$86.25 - $120.16 $3.34 Million - $4.65 Million
-38,712 Reduced 21.61%
140,442 $14 Million
Q2 2019

Aug 09, 2019
SELL
$107.38 - $129.34 $2.26 Million - $2.72 Million
-21,037 Reduced 10.51%
179,154 $20.5 Million
Q1 2019

May 14, 2019
BUY
$105.93 - $142.47 $1.82 Million - $2.45 Million
17,189 Added 9.39%
200,191 $25.2 Million
Q4 2018

Feb 14, 2019
BUY
$128.36 - $272.13 $1.31 Million - $2.77 Million
10,180 Added 5.89%
183,002 $24.8 Million
Q3 2018

Nov 13, 2018
BUY
$211.18 - $274.49 $7.8 Million - $10.1 Million
36,951 Added 27.2%
172,822 $47.4 Million
Q2 2018

Aug 08, 2018
BUY
$150.77 - $207.98 $234,899 - $324,032
1,558 Added 1.16%
135,871 $28.1 Million
Q1 2018

May 07, 2018
BUY
$138.63 - $182.62 $495,047 - $652,136
3,571 Added 2.73%
134,313 $22.2 Million
Q4 2017

Jan 17, 2018
BUY
$128.36 - $147.04 $378,662 - $433,768
2,950 Added 2.31%
130,742 $17.9 Million
Q3 2017

Nov 13, 2017
BUY
$120.91 - $137.94 $15.5 Million - $17.6 Million
127,792
127,792 $17.4 Million

Others Institutions Holding LGND

# of Institutions
234
Shares Held
16.5M
Call Options Held
77.9K
Put Options Held
25K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.42B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email